Table 2.

Cells with copy number variations (CNVs) of chromosomes 3, 7, 17 and at 9p21 in cases by subtype of bladder tumor in urine samples collected in the year before diagnosis

CNV			0	1	2	3	4	≥5	Total	Loss (CNV <2)	Gain (CNV >2)
All cases	CEP 3	N (%)	2 (0.3)	0 (0)	554 (87.4)	26 (4.1)	37 (5.8)	15 (2.4)	634 (100)	2 (0.3)	78 (12.3)
	CEP 7	N (%)	2 (0.3)	2 (0.3)	547 (86.3)	26 (4.1)	46 (7.3)	11 (1.7)	634 (100)	4 (0.6)	83 (13.1)
	CEP 17	N (%)	2 (0.3)	3 (0.5)	552 (87.1)	24 (3.8)	35 (5.5)	18 (2.8)	634 (100)	5 (0.8)	77 (12.1)
	LSI 9p21	N (%)	22 (3.5)	8 (1.3)	567 (89.4)	15 (2.4)	21 (3.3)	1 (0.2)	634 (100)	30 (4.7)	37 (5.8)
Papilloma (2 cases, 3 samples)	CEP 3	N (%)	0 (0)	0 (0)	83 (97.6)	0 (0)	2 (2.4)	0 (0)	85 (100)	0 (0)	2 (2.4)
	CEP 7	N (%)	0 (0)	1 (1.2)	83 (97.6)	0 (0)	1 (1.2)	0 (0)	85 (100)	1 (1.2)	1 (1.2)
	CEP 17	N (%)	0 (0)	0 (0)	83 (97.6)	0 (0)	2 (2.4)	0 (0)	85 (100)	0 (0)	2 (2.4)
	LSI 9p21	N (%)	0 (0)	0 (0)	83 (97.6)	1 (1.2)	1 (1.2)	0 (0)	85 (100)	0 (0)	2 (2.4)
Low-grade bladder cancer (5 cases, 6 samples)	CEP 3	N (%)	0 (0)	0 (0)	159 (90.9)	3 (1.7)	7 (4.0)	6 (3.4)	175 (100)	0 (0)	16 (9.1)
	CEP 7	N (%)	0 (0)	0 (0)	156 (89.1)	8 (4.6)	7 (4.0)	4 (2.3)	175 (100)	0 (0)	19 (10.9)
	CEP 17	N (%)	0 (0)	0 (0)	160 (91.4)	7 (4.0)	5 (2.9)	3 (1.7)	175 (100)	0 (0)	15 (8.6)
	LSI 9p21	N (%)	2 (1.1)	0 (0)	163 (93.1)	7 (4.0)	3 (1.7)	0 (0)	175 (100)	2 (1.1)	10 (5.7)
High-grade bladder cancer (9 cases, 12 samples)	CEP 3	N (%)	2 (0.5)	0 (0)	312 (83.4)	23 (6.1)	28 (7.5)	9 (2.4)	374 (100)	2 (0.5)	60 (16.0)
	CEP 7	N (%)	2 (0.5)	1 (0.3)	308 (82.4)	18 (4.8)	38 (10.2)	7 (1.9)	374 (100)	3 (0.8)	63 (16.8)
	CEP 17	N (%)	2 (0.5)	3 (0.8)	309 (82.6)	17 (4.5)	28 (7.5)	15 (4.0)	374 (100)	5 (1.3)	60 (16.0)
	LSI 9p21	N (%)	20 (5.3)	8 (2.1)	321 (85.8)	7 (1.9)	17 (4.5)	1 (0.3)	374 (100)	28 (7.5)	25 (6.7)